For example, inhibition of BTK, PI3K and SYK through ibrutinib [11,12], idelalisib [13], and fostamatinib [14,15], respectively, has been shown to be effective in follicular lymphoma, mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL). The gene discussed is PIK3CA; the disease is B-cell chronic lymphocytic leukemia.